#### NOVADEL PHARMA INC

Form 4

August 29, 2007

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**SECURITIES** 

**OMB** Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

response...

**OMB APPROVAL** 

Check this box if no longer subject to Section 16. Form 4 or Form 5

obligations may continue. See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* Baric Mark J

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

NOVADEL PHARMA INC [NVD]

(Check all applicable)

(Last)

(City)

(First)

(Middle)

(Zip)

3. Date of Earliest Transaction

(Month/Day/Year)

08/28/2007

X\_ Director 10% Owner Officer (give title Other (specify

MARK J. BARIC, C/O NOVADEL PHARMA, 25 MINNEAKONING **ROAD** 

(State)

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

FLEMINGTON, NJ 08822

|                     | 14010              |                                       |   |  |  | lanca, Ensposea c  | ,, 01 20110110111   | -j   |
|---------------------|--------------------|---------------------------------------|---|--|--|--|---|--|
| 2. Transaction Date | 2A. Deemed         | 3.                                    | 4. Securities Acquired  |  | 5. Amount of   | 6. Ownership   | 7. Nature of  |  |
| (Month/Day/Year)    | Execution Date, if | Transaction(A) or Disposed of         |   |  |  | Securities   | Form: Direct  | Indirect   |
| •                   | any                | Code                                  | le (D)  |  |  | Beneficially   | (D) or  | Beneficial   |
|                     | (Month/Day/Year)   | (Instr. 8)                            | (Instr. 3, 4 and 5)   |  |  | Owned  | Indirect (I)  | Ownership  |
|                     | ` ,                |                                       |   |  | Following  | (Instr. 4)   | (Instr. 4)  |  |
|                     |                    |                                       | 4.5   |  | Reported   |  |   |  |
|                     |                    |                                       |   |  |  | Transaction(s)   |   |  |
|                     |                    |                                       |   |  | ~ .  | (Instr. 3 and 4)   |   |  |
|                     |                    | Code V                                | Amount  | (D)  |  | · ·  |   |  |
| 00/20/2007          |                    | D                                     | 100   | ٨  | \$   | 100  | D   |  |
| 00/20/2007          |                    | r                                     | 100   | A  | 0.69   | 100  | D   |  |
|                     |                    |                                       |   |  |  |  |   |  |
| 09/20/2007          |                    | D                                     | 4.000   | ٨  | \$ 0 9   | 5.000  | D   |  |
| 08/29/2007          |                    | r                                     | 4,900   | A  | \$ 0.0   | 3,000  | D   |  |
|                     |                    | any<br>(Month/Day/Year)<br>08/28/2007 | 2. Transaction Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Month/Day/Year) Code (Instr. 8)  Code V  08/28/2007 P | 2. Transaction Date 2A. Deemed 3. 4. Securi (Month/Day/Year) Execution Date, if any Code (D) (Month/Day/Year) (Instr. 8) (Instr. 3, Code V Amount 08/28/2007 P 100 | 2. Transaction Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and (A) or Code V Amount (D)  08/28/2007 P 100 A | 2. Transaction Date (Month/Day/Year)    2. Transaction Date (Month/Day/Year)    Execution Date, if any (Month/Day/Year)    (Month/Day/Year)    (Month/Day/Year)    (A) or (Code V Amount (D) Price P 100 A \$ 0.69 | 2. Transaction Date (Month/Day/Year) Execution Date, if any (Month/Day/Year) (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Execution Securities Beneficially (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Owned Following Reported Transaction(s) (Instr. 3 and 4)  Code V Amount (D) Price P 100 A \$ 100 | (Month/Day/Year) Execution Date, if any (Code (D) (Instr. 8) (Instr. 3, 4 and 5) (Instr. 4) Execution (Solution (A)) or Disposed of any (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) (Instr. 4) Execution Date, if any (Code (D)) (Instr. 8) (Instr. 3, 4 and 5) (Instr. 4) Execution Date, if any (D) or (Instr. 4) (Instr. 4) (Instr. 4) (Instr. 4) (Instr. 3 and 4) (Instr. 3 and 4) (Instr. 3 and 4) (Instr. 3 and 4) |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

### Edgar Filing: NOVADEL PHARMA INC - Form 4

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative | 2. Conversion                                     | 3. Transaction Date (Month/Day/Year) |                      | 4.<br>Transacti    | 5.<br>onNumber | 6. Date Exerc<br>Expiration D |                    | 7. Title Amount      |        | 8. Price of Derivative | 9. Nu<br>Deriv  |
|------------------------|---|--------------------------------------|----------------------|--------------------|----------------|-------------------------------|--------------------|----------------------|--------|------------------------|---|
| Security<br>(Instr. 3) | or Exercise<br>Price of<br>Derivative<br>Security | (Mondin Day) Tear)                   | any (Month/Day/Year) | Code<br>(Instr. 8) | of             | (Month/Day/Year) ve es d      |                    | Underly<br>Securitie | rlying | Security (Instr. 5)    | Secur<br>Bene<br>Owne<br>Follo<br>Repo<br>Trans<br>(Instr |
|                        |   |                                      |                      | Code V             | (A) (D)        | Date<br>Exercisable           | Expiration<br>Date | Title N              | Number |                        |   |

## **Reporting Owners**

Reporting Owner Name / Address Relationships

X

Director 10% Owner Officer Other
Baric Mark J

C/O NOVADEL PHARMA, 25 MINNEAKONING ROAD FLEMINGTON, NJ 08822

## **Signatures**

MARK J. BARIC

/s/ Mark J. Baric 08/29/2007

\*\*Signature of Person Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2